Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye.
$7.49+9.66%
报价 2026-11-06
市值
$462.4M
EV
–
PE (TTM)
–
预期 PE
–
52 周区间距高点 -77.1%
$6.83$32.65
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| OCSOculis Holding AG | $462.4M | +9.7% | – | -2,889.4% | – | – | – | |
| CBIOCrescent Biopharma, Inc. | $502.9M | +4.6% | -76.0% | 100% | – | – | – | |
| MDXGMiMedx Group, Inc. | $483M | +0.9% | -30.8% | 82.6% | 12.9x | 6.0x | 6.9x | |
| MNPRMonopar Therapeutics Inc. | $479.4M | +6.2% | – | 0% | – | – | – | |
| CTMXCytomX Therapeutics, Inc. | $477.2M | +2.3% | -60.2% | 99.3% | – | – | – | |
| STTKShattuck Labs, Inc. | $463.7M | +2.9% | +33.3% | -82% | – | – | – | |
| EPRXEupraxia Pharmaceuticals Inc. | $455.2M | +4.4% | – | 0% | – | – | – | |
| PHATPhathom Pharmaceuticals, Inc. | $426.8M | +3.3% | +91.4% | 87.1% | – | – | – | |
| PBYIPuma Biotechnology, Inc. | $425.9M | -15.6% | +0.2% | 74.5% | 10.1x | 5.4x | 10.1x | |
| 同行中位数 | – | – | -15.3% | 78.5% | 11.5x | 5.7x | 8.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
报告货币 CHF（非美元）暂无季度数据（首次研究运行后填充）。